Castlight Health Inc (NYSE:CSLT) has been assigned a consensus rating of “Hold” from the ten research firms that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $5.18.

A number of brokerages have recently issued reports on CSLT. BidaskClub downgraded shares of Castlight Health from a “sell” rating to a “strong sell” rating in a report on Thursday, November 9th. Zacks Investment Research upgraded shares of Castlight Health from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a report on Monday, October 30th. Canaccord Genuity reiterated a “buy” rating and issued a $7.00 target price on shares of Castlight Health in a report on Thursday, October 26th. Chardan Capital dropped their target price on shares of Castlight Health from $6.50 to $6.30 and set a “buy” rating for the company in a report on Thursday, October 26th. Finally, Cantor Fitzgerald reiterated a “hold” rating and issued a $5.00 target price on shares of Castlight Health in a report on Wednesday, October 25th.

In other Castlight Health news, CFO Mangini Siobhan Nolan sold 8,866 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $3.70, for a total value of $32,804.20. Following the completion of the transaction, the chief financial officer now owns 78,561 shares of the company’s stock, valued at approximately $290,675.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO John C. Doyle sold 13,686 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $3.71, for a total transaction of $50,775.06. Following the completion of the transaction, the chief executive officer now directly owns 123,705 shares of the company’s stock, valued at approximately $458,945.55. The disclosure for this sale can be found here. Insiders sold a total of 22,778 shares of company stock valued at $84,411 in the last quarter. 37.43% of the stock is owned by insiders.

A number of hedge funds have recently modified their holdings of CSLT. Voya Investment Management LLC boosted its position in Castlight Health by 25.4% in the 2nd quarter. Voya Investment Management LLC now owns 26,929 shares of the software maker’s stock valued at $112,000 after buying an additional 5,453 shares during the period. Nationwide Fund Advisors boosted its position in Castlight Health by 49.5% in the 2nd quarter. Nationwide Fund Advisors now owns 36,418 shares of the software maker’s stock valued at $151,000 after buying an additional 12,061 shares during the period. Stifel Financial Corp boosted its position in Castlight Health by 12.3% in the 2nd quarter. Stifel Financial Corp now owns 41,000 shares of the software maker’s stock valued at $171,000 after buying an additional 4,500 shares during the period. UBS Asset Management Americas Inc. purchased a new position in Castlight Health in the 2nd quarter valued at approximately $193,000. Finally, New York State Common Retirement Fund boosted its position in Castlight Health by 60.5% in the 2nd quarter. New York State Common Retirement Fund now owns 49,600 shares of the software maker’s stock valued at $206,000 after buying an additional 18,699 shares during the period. 42.55% of the stock is owned by institutional investors.

Shares of Castlight Health (NYSE CSLT) opened at $3.75 on Monday. The stock has a market cap of $501.51, a P/E ratio of -7.81 and a beta of 1.66. The company has a current ratio of 1.94, a quick ratio of 1.94 and a debt-to-equity ratio of 0.03. Castlight Health has a 1-year low of $3.05 and a 1-year high of $5.10.

Castlight Health (NYSE:CSLT) last announced its quarterly earnings results on Wednesday, October 25th. The software maker reported ($0.05) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.07) by $0.02. The business had revenue of $34.60 million during the quarter, compared to the consensus estimate of $34.61 million. Castlight Health had a negative net margin of 45.14% and a negative return on equity of 32.57%. The business’s revenue was up 35.7% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.05) EPS. research analysts forecast that Castlight Health will post -0.43 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Castlight Health Inc (CSLT) Given Average Recommendation of “Hold” by Brokerages” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://theolympiareport.com/2018/01/01/castlight-health-inc-cslt-given-average-recommendation-of-hold-by-brokerages.html.

About Castlight Health

Castlight Health, Inc offers a health benefits platform that engages employees to make healthcare decisions, and enables employers to communicate and measure their benefit programs. The Company operates through cloud-based products segment. Its technology offering aggregates data and applies analytics to make healthcare data transparent.

Analyst Recommendations for Castlight Health (NYSE:CSLT)

Receive News & Ratings for Castlight Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castlight Health and related companies with MarketBeat.com's FREE daily email newsletter.